Chronic Pancreatitis, Pancreatic Cysts, and Pancreatic Neoplasms

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 26.1: Etiology (TIGAR-O) and severity grading (M-ANNHEIM)

  Chronic pancreatitis is defined mechanistically as a pathologic fibroinflammatory syndrome of the pancreas in patients with genetic, environmental, or other risk factors who develop a persistent pathologic response to parenchymal injury or stress.

• Section 26.2: Genetic chronic pancreatitis

  PRSS1 (cationic trypsinogen, common pathogenic variants p.R122H and p.N29I) causes hereditary pancreatitis through a gain-of-function mechanism in which the mutated trypsinogen escapes inactivation and produces excessive intrapancreatic trypsin activity, driving recurrent autodigestion.

• Section 26.3: Diagnostic ladder

  Diagnosis integrates clinical symptoms, structural imaging, and functional testing because no single biomarker is accurate and histology is rarely available.

• Section 26.4: Pain management and ESCAPE

  Pain in chronic pancreatitis is multifactorial.

• Section 26.5: PERT and exocrine insufficiency

  Steatorrhea, weight loss, and fat-soluble vitamin A, D, E, and K deficiency appear only after exocrine reserve drops below approximately 10 percent of normal because the pancreas has substantial functional reserve; modest gland injury produces measurable function tests but no clinical malabsorption, while clinically apparent exocrine insufficiency implies advanced parenchymal loss.

• Section 26.6: Type 3c diabetes

  The American Diabetes Association recognizes type 3c diabetes as distinct from type 2.

• Section 26.7: Autoimmune pancreatitis types 1 and 2

  Type 1 autoimmune pancreatitis is lymphoplasmacytic sclerosing pancreatitis, the pancreatic manifestation of IgG4-related disease (cross-link Ch 20 for IgG4-related disease beyond the pancreas, including IgG4-associated cholangitis).

• Section 26.8: Chronic pancreatitis complications

  Pseudocyst occurs in approximately 25 percent of chronic pancreatitis patients (most often alcoholic chronic pancreatitis) as a mature peripancreatic fluid collection with non-epithelialized fibrous wall, formed at least 4 weeks after an acute episode or arising from ductal disruption in established disease.

• Section 26.9: Pancreatic cyst classification

  The five entities to distinguish on cross-sectional imaging plus EUS are IPMN, MCN, SCA, SPEN, and pseudocyst.

• Section 26.10: Cyst fluid analysis

  Cyst fluid CEA greater than 192 ng per mL favors mucinous origin (sensitivity approximately 73 percent, specificity 84 percent) because mucinous epithelium secretes CEA; CEA below 5 ng per mL has 85 percent specificity for excluding mucinous origin.

• Section 26.11: IPMN Fukuoka and Kyoto guidelines

  The Fukuoka 2017 international consensus and the updated Kyoto 2024 evidence-based guidelines define worrisome features and high-risk stigmata that drive management of branch-duct IPMN.

• Section 26.12: IPMN surveillance intervals

  Branch-duct IPMN without worrisome features is surveilled by size, with intervals reflecting the size-stratified malignancy risk.

• Section 26.13: Pancreatic adenocarcinoma diagnosis and management

  Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States and arises in the pancreatic head in 60 to 70 percent of cases, which is why obstructive jaundice (present in approximately 55 percent at diagnosis) is the dominant clinical signature.

• Section 26.14: Pancreatic neuroendocrine tumors

  Pancreatic neuroendocrine tumors (pNETs) arise from islet-derived endocrine cells and are mechanistically distinct from ductal adenocarcinoma.

Podcast episodes

1. 01

   Chronic Pancreatitis Framework and Pain

   Episode one of the Chronic Pancreatitis, Cysts, and Neoplasms chapter builds the framework from a single fact: fewer than three percent of heavy drinkers ever develop the disease, so exposure alone is never enough and a co-modifier has to do the converting. The organizing idea is that tobacco and a genetic background decide who progresses, and where each gene sits in the trypsin-control pathway sets its inheritance, penetrance, and cancer risk. Diagnosis is calibrated to stage, CT for calcification, secretin-MRCP for the duct, endoscopic ultrasound for minimal-change parenchyma, and function testing for the gland that still looks normal. Pain is worked in steps, from cessation and non-opioid analgesics through neuromodulators to decompression, with the randomized shift that moved early surgery ahead of endoscopy the tested pivot. Cause, mechanism, staging, and steps throughout.

   Read the transcript →
2. 02

   Enzyme Replacement, Type 3c Diabetes, Complications

   Episode two follows three threads that all trace to the same parenchymal loss the framework episode set up. The acini die and enzyme replacement stands in, but only if dosed with the meal and released at the right duodenal pH, so a proton pump inhibitor enters when the coating fails. The islets die and produce a diabetes defined not by insulin lack but by lost glucagon, which makes hypoglycemia the dominant management feature and steers drug choice away from sulfonylureas. The structural disruption produces complications whose management is read directly off the anatomy, drain the symptomatic pseudocyst, recognize disconnected duct as the exception, and take the spleen out when left-sided portal hypertension bleeds. Mechanism first, management second, throughout.

   Read the transcript →
3. 03

   Autoimmune Pancreatitis Types One and Two

   Episode three steps outside the alcohol-and-tobacco gland to a diagnosis that sits at a costly decision point: steroids given to a patient who actually has adenocarcinoma cost the curative resection window. Autoimmune pancreatitis splits on mechanism, type one a systemic IgG4-related plasma-cell disease of older men with painless jaundice, type two a duct-centered process a decade younger tied to inflammatory bowel disease. Demographics, imaging, serology, other-organ involvement, and histology all line up behind that one distinction, and the criteria are structured precisely because the mass mimics cancer. The steroid trial is pulled in as a diagnostic element, but when the differential with adenocarcinoma stays genuinely unresolved, surgery comes first. Mechanism drives the whole call.

   Read the transcript →
4. 04

   Pancreatic Cystic Lesions and Surveillance

   Episode four takes the incidental cyst through the same endoscopic-ultrasound-and-fluid pathway used for the autoimmune mass, but the cost runs the other way: resecting a cyst that was never going to become cancer commits a patient to major-operation morbidity for nothing. The organizing question is whether the epithelium is mucinous, because only the mucinous lesions carry progressive dysplasia, and the fluid answers it, CEA and glucose for mucin, amylase for duct communication. Demographics and imaging give a pretest guess, then the biochemistry classifies the lesion cleanly. The intraductal mucinous neoplasm is the one left to surveil, where high-risk stigmata mandate resection, worrisome features trigger endoscopic ultrasound, and a size-stratified MRI schedule runs only while it can still change management. Thresholds are the trap throughout.

   Read the transcript →
5. 05

   Pancreatic Adenocarcinoma and Neuroendocrine Tumors

   Episode five closes the chapter with two tumors that share the same pancreas and almost nothing else. Adenocarcinoma is desmoplastic, poorly enhancing, presents late with painless jaundice, and is staged by its relationship to four vessels into the resectability categories that drive surgery-versus-systemic-therapy. The neuroendocrine tumors are islet-derived, hypervascular, and often announce themselves with a hormone syndrome while still small, sorted by functional pattern and grade. The same core biopsy and multiphase CT serve both, but everything downstream diverges, so the work is holding the two algorithms apart. Biology sets the staging language, and the staging language sets the treatment, from neoadjuvant FOLFIRINOX to somatostatin analogs and radionuclide therapy.

   Read the transcript →

Key topics

• ·Fibroinflammatory disease and the co-modifier concept
• ·Tobacco and genetic background as converters
• ·TIGAR-O etiologic classification
• ·Genetic forms and trypsin regulation
• ·Cationic trypsinogen cancer risk and surveillance
• ·Staged diagnosis: CT, secretin-MRCP, endoscopic ultrasound
• ·Functional testing for early disease
• ·Stepwise pain management
• ·Early surgery in dilated-duct disease
• ·Exocrine reserve and the ten-percent threshold
• ·Enzyme replacement dosing with meals
• ·Structured workup for inadequate response
• ·Pancreatogenic diabetes and lost glucagon
• ·Drug choices: metformin over sulfonylureas
• ·Pseudocyst and disconnected duct syndrome
• ·Distal bile duct stricture from head fibrosis
• ·Splenic vein thrombosis and left-sided portal hypertension
• ·Pancreatic ascites and pseudoaneurysm
• ·Mechanism split: plasma-cell versus duct-centered
• ·Demographics of type one and type two
• ·Imaging and the absent double-duct sign
• ·IgG4 serology and its threshold
• ·Other-organ involvement
• ·Histology: storiform fibrosis versus granulocytic lesion
• ·Steroid response as a diagnostic element
• ·When surgery precedes the steroid trial
• ·Relapse pattern and rituximab
• ·Mucinous versus non-mucinous as the organizing principle
• ·Demographics and imaging of the five entities
• ·Mucinous cystic neoplasm versus serous cystadenoma